4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Polaryx Therapeutics, Inc. (PLYX) operates in the Biotechnology industry and is headquartered in Paramus, United States with about 2 employees. Its market capitalization is roughly $115 million. In the fiscal year ended 2025-12-31, PLYX reported $0M in revenue and ($9M) in net income.
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Revenue | $0M | $0M | $0M |
| Operating Income (EBIT) | ($8M) | ($4M) | ($4M) |
| Net Income | ($9M) | ($30M) | ($4M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($2M) | ($1M) | ($1M) | ($1M) | ($5M) | — |
| Net Income | ($2M) | ($2M) | ($1M) | ($1M) | ($5M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets | $5M | $5M | $2M |
| Total Liabilities | $1M | $0M | $1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PLYX viewer.
About TickerBase · Data methodology & sources